- Home
- NTRA
NTRA
Natera Inc.
as 07-01-2025 3:40pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 21.5B | IPO Year: | 2015 |
| Target Price: | $185.56 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $92.14 - $183.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | $1,831,000,000 | Revenue Growth: | 51.50% |
| Revenue Growth (this year): | 19.92% | Revenue Growth (next year): | 16.02% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Jun 2 '25 | Sell | $157.76 | 3,000 | $471,212.07 | 134,915 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jun 2 '25 | Sell | $157.14 | 6,111 | $960,062.44 | 183,670 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | May 15 '25 | Sell | $156.11 | 54,000 | $8,384,150.00 | 45,000 | |
| Sheena Jonathan | NTRA | Director | May 9 '25 | Sell | $158.88 | 6,070 | $966,632.61 | 251,844 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | May 1 '25 | Sell | $150.39 | 3,000 | $450,353.06 | 134,915 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | May 1 '25 | Sell | $150.37 | 6,980 | $1,047,702.42 | 183,670 | |
| Marcus Gail Boxer | NTRA | Director | May 1 '25 | Sell | $149.99 | 4,000 | $606,432.75 | 12,768 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Apr 28 '25 | Sell | $152.18 | 2,206 | $335,714.37 | 134,915 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Apr 28 '25 | Sell | $152.18 | 1,993 | $303,299.52 | 223,674 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Apr 28 '25 | Sell | $152.18 | 1,709 | $260,079.72 | 155,237 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target
StockStory
9 days ago
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
StockStory
12 days ago
3 Reasons We Love Natera (NTRA)
Simply Wall St.
13 days ago
High Growth US Tech Stocks To Watch In June 2025
StockStory
22 days ago
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
MT Newswires
a month ago
Natera Says Signatera Cancer Test Approved for Medicare Coverage
Business Wire
a month ago
Natera Announces Medicare Coverage for Signatera™ Genome
Simply Wall St.
a month ago
Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.